Can the risk of retinal pigment epithelium tears after bevacizumab treatment be predicted? An optical coherence tomography study

Eye (Lond). 2008 Dec;22(12):1504-7. doi: 10.1038/eye.2008.145. Epub 2008 Jun 6.

Abstract

Background: Retinal pigment epithelium (RPE) tears after bevacizumab treatment for neovascular age-related macular degeneration accompanied by a pigment epithelial detachment (PED) might be caused by stretching forces on the already weakened RPE. The purpose of this study was to evaluate whether simple measurements of optical coherence tomography (OCT) can predict the individual risk of an RPE tear in preoperative candidates.

Methods: A retrospective chart review study of 393 consecutive patients with neovascular age-related macular degeneration evaluated OCT images (Stratus-OCT Zeiss, Jena, Germany). The height of the PED, the central retinal thickness, and the maximum retinal thickness were determined by two independent observers and retrospectively analysed.

Results: Fifteen patients with an RPE tear had a significant higher PED than the remaining study population. In contrast, no correlation was seen with the central retinal thickness. In a linear regression model, the probability of an RPE tear exponentially increased in dependence of the extent of PED.

Conclusion: The risk of an RPE tear can be estimated by simple measurement of the height of the PED on OCT.

MeSH terms

  • Angiogenesis Inhibitors / adverse effects*
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Humans
  • Macular Degeneration / complications
  • Macular Degeneration / drug therapy*
  • Macular Degeneration / pathology
  • Retinal Detachment / complications
  • Retinal Detachment / drug therapy*
  • Retinal Detachment / pathology
  • Retinal Perforations / chemically induced*
  • Retinal Perforations / pathology
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Tomography, Optical Coherence

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab